Cocaine: maternal use during pregnancy and its effect on the mother, the fetus, and the infant.
Cocaine was previously regarded as a soft drug causing only mild damage. Its use during pregnancy, however, creates a variety of grave medical problems which necessitate immediate attention not only on the part of internists and psychiatrists but also, and more particularly, by obstetricians and pediatricians. The pregnancy of a cocaine-using woman must be carefully managed and regarded as a high-risk one. This in view of the numerous obstetric risks caused by the drug, notably premature separation of the placenta, increased incidence of stillbirths, congenital malformations, premature births, and intrauterine growth retardation. The neonatal monitoring must be focused on prevention of complications resulting from the withdrawal syndrome and associated conditions such as pneumonia, severe weight loss, and contagion from the mother. Moreover, efforts must be made to ensure a strict observation of the infant outside the hospital in view of the far greater incidence of idiopathic infant death in such cases. Owing to the sharp rise of the regular and occasional use of the drug and since pregnant women tend on anamnesis to deny any drug taking, we recommend a test of maternal urine for cocaine and other drugs whenever a suspicion to this effect arises. It is also advisable to test for the presence of such drugs in the urine of the neonate in cases of reasonable suspicion of maternal use during pregnancy, though a negative outcome of the urine test naturally does not rule out a possible use. Strict monitoring of positive cases, accompanied by preventive treatment, may contribute a great deal toward a reduction of perinatal morbidity and mortality associated with cocaine use use.
Department of Obstetrics and Gynecology, Bikur Cholim Hospital, Jerusalem, Israel.
D
D
Rosenak
Y Z
YZ
Diamant
H
H
Yaffe
E
E
Hornstein
D003042:Cocaine / Q000494:pharmacology; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced*; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000139:chemically induced*; D008431:Maternal-Fetal Exchange; D009357:Neonatal Abstinence Syndrome / Q000209:etiology*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000503:physiopathology*; D019966:Substance-Related Disorders / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy
D003042:Cocaine